Johns Hopkins Tests KRAS Vaccine in 20 High-Risk Pancreatic Patients, Showing Early Prevention Promise
Updated
Updated · Oncodaily · Jul 22
Johns Hopkins Tests KRAS Vaccine in 20 High-Risk Pancreatic Patients, Showing Early Prevention Promise
3 articles · Updated · Oncodaily · Jul 22
Summary
Early Johns Hopkins data highlighted by Anna Berkenblit point to a mutant KRAS vaccine aimed at preventing pancreatic cancer in people with pancreatic cysts who face elevated risk.
In a first-in-human phase 1 trial, 20 high-risk patients received mKRAS-VAX; none developed pancreatic cancer after 16.5 months, 37.5% had cyst shrinkage, and 90% mounted an immune response.
The vaccine targets six common KRAS mutations, a key driver in more than 90% of pancreatic ductal adenocarcinomas, and was reported as safe and well tolerated.
The update comes as KRAS-targeting therapies for treating pancreatic cancer move closer, extending the focus from therapy toward interception and prevention in high-risk groups.
As a vaccine shows promise against pancreatic cancer, are we entering a new era of cancer prevention?
With AI predicting risk and vaccines preventing onset, how will a genetic cancer diagnosis change for patients?
mKRAS-VAX Vaccine Shows 0% Pancreatic Cancer Progression in Phase 1: A Breakthrough in Preventive Oncology
Overview
The recent Phase 1 clinical trial results for mKRAS-VAX, announced on July 21, 2026, mark a hopeful advance for people at high risk of pancreatic cancer. The trial focused on safety and early effectiveness in a high-risk group, and over a median follow-up of 16.5 months, no vaccinated patients developed pancreatic cancer or high-risk lesions needing surgery. This encouraging outcome suggests that mKRAS-VAX has a favorable safety profile and may offer real protection against disease progression, highlighting its potential as a preventive option for this aggressive cancer.